Rituximab treatment of mild haemophilia A with inhibitors: A proposed treatment protocol

Haemophilia

Volumn 12, Issue 6, 2006, Pages 663-667

  Dunkley, Scott ^a   Kershaw, G ^a   Young, G ^a   Warburton, P ^b   Lindeman, R ^c   Matthews, S ^a   Rennisson, F ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b WOLLONGONG HOSPITAL   (Australia)

^c PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

Immune tolerance induction; Inhibitors; Mild haemophilia A; Rituximab

Indexed keywords

BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 8; RITUXIMAB;

ADULT; AGED; ARTICLE; CASE REPORT; CHOLECYSTECTOMY; CONTINUOUS INFUSION; DISEASE SEVERITY; DRUG EXPOSURE; DRUG RESPONSE; HEMARTHROSIS; HEMATURIA; HEMOPHILIA A; HERNIOPLASTY; HOSPITAL ADMISSION; HUMAN; INGUINAL HERNIA; MAINTENANCE THERAPY; MALE; PRIORITY JOURNAL; RELAPSE; REMISSION; RETROSPECTIVE STUDY; SINGLE DRUG DOSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; HEMOPHILIA A; HUMANS; IMMUNE TOLERANCE; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 33750693405     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2006.01351.x     Document Type: Article

References (21)

1. Hay CR. Factor.VIII inhibitors in mild and moderate-severity haemophilia A. Haemophilia 1998; 4: 558-63.
2. Darby SC, Keeling DM, Spooner RJD et.al. The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99. J Thromb Haemost 2004; 2: 1047-54.
3. Key NS. Inhibitors in congenital coagulation disorders. Br J Haematol 2004; 4: 379-91.
4. d'Oiron R, Volot F, Reynaud J et.al. Impact of choice of treatment for bleeding episodes on inhibitor outcome in patients with mild/moderate hemophilia a and inhibitors. Semin Hematol 2006; 43(Suppl. 1): S3-9.
5. Saint-Remy JM, Lacroix-Desmazes S, Oldenburg J. Inhibitors in haemophilia: Pathophysiology. Haemophilia 2004; 10(Suppl. 4): 146-51.
6. Sharathkumar A, Lillicrap D, Blanchette VS, Kern M, Leggo J, Stain AM et.al. Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A. J Thromb Haemost 2003; 1: 1228-36, 2003.
7. Hay CR, Ludlam CA, Colvin BT et.al. Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation. J Thromb Haemost 1998; 79: 762-6.
8. Mathias M, Khair, K, Hann I, Liesner R. Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia. Br J Haematol 2004; 125: 366-8.
9. Stasi R, Brunetti M, Stipa E, Amadori S. Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia. Blood 2004; 103: 4424-8.
10. Dunkley S, Lindeman R. Successful treatment of a high titre factor VIII inihibitor with Rituximab alone. J Thromb Haemost 2005; 3(Suppl. 1): Abstract no. P0631.
11. Carcao M, St. Louis J, Poon MC et.al. Rituximab for congenital haemophiliacs with inhibitors: A Canadian experience. Haemophilia 2006; 12: 7-18.
12. Pruthi RK, Schmidt KA, Slaby JA, Hook CC, Nichols WL. Rituximab treatment of FVIII inhibitors in congenital haemophilia A.(cHA). J Thromb Haemost 2005; 3 (Suppl. 1): Abstract no. P0652.
13. Wiestner A, Cho HJ, Asch AS et al. Rituximab in the treatment of acquired factor VIII inhibitors. Blood 2002; 100: 3426-8.
14. Trapp R, Riess H. Rituximab in the teatment of alloimmune factor Viii antibodies in an adult with mild haemophilia. Haemophilia 2006; 12(Suppl. 2): 57-69.
15. Reff ME, Carner K, Chambers KS. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435-45.
16. Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenia purpura. Blood 2001; 98: 952-7.
17. Binstadt BA, Caldas AM, Turvey SE et.al. Rituximab therapy for multisystem autoimmune disease in pediatric patients. J Pediatr 2003; 143: 598-604.
18. Hausl C, Ahmad R, Doering C et al. High dose factor VIII inhibits factor VIII -specific memory B cells in hemophilia A with factor VIII inhibitors. Blood 2005; 106: 3415-22.
19. Curry N, Stanworth S, Keeling D. The use of rituximab in two children with allo-antibodies toward factor VIII. Br J Haematol 2006; 133: 214-6.
20. Buske C, Hiddemannn W. Rituximab maintenance therapy in indolent NHL: A clinical review. Leuk Res 2006; 30: S11-5.
21. Hainsworth JD, Litchy S, Burris HA, et.al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 4261-7.